CA2186867C - Methodes d'utilisation de chelates contenant du fer pour diminuer les atteintes dues aux radicaux libres chez les mammiferes - Google Patents

Methodes d'utilisation de chelates contenant du fer pour diminuer les atteintes dues aux radicaux libres chez les mammiferes Download PDF

Info

Publication number
CA2186867C
CA2186867C CA002186867A CA2186867A CA2186867C CA 2186867 C CA2186867 C CA 2186867C CA 002186867 A CA002186867 A CA 002186867A CA 2186867 A CA2186867 A CA 2186867A CA 2186867 C CA2186867 C CA 2186867C
Authority
CA
Canada
Prior art keywords
furilmonoxime
furildioxime
composition
piroctone
safe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002186867A
Other languages
English (en)
Other versions
CA2186867A1 (fr
Inventor
Donald L. Bissett
Steven Alan Shaya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procter and Gamble Co
Original Assignee
Procter and Gamble Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter and Gamble Co filed Critical Procter and Gamble Co
Publication of CA2186867A1 publication Critical patent/CA2186867A1/fr
Application granted granted Critical
Publication of CA2186867C publication Critical patent/CA2186867C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une méthode pour diminuer les atteintes dues aux radicaux libres chez les mammifères consistant à administrer à un mammifère une quantité suffisante mais sans danger pour la santé d'un composé choisi parmi les composés suivants: 1-phényl-1,2-propanedione-2-oxime, benzoylacétone, piroctone, 2-furyldioxime, 2-furylmonoxime, acide diéthyldithiocarbamique, déféroxamine, 1,2-diméthyl-3-hydroxy-pyrid-4-one, un sel d'un de ceux-ci acceptable sur le plan pharmaceutique, les mélanges de ces composés et/ou leurs sels.
CA002186867A 1994-04-08 1995-03-06 Methodes d'utilisation de chelates contenant du fer pour diminuer les atteintes dues aux radicaux libres chez les mammiferes Expired - Fee Related CA2186867C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22494994A 1994-04-08 1994-04-08
US08/224,949 1994-04-08
PCT/US1995/002872 WO1995027485A1 (fr) 1994-04-08 1995-03-06 Methodes d'utilisation de chelates contenant du fer pour diminuer les atteintes dues aux radicaux libres chez les mammiferes

Publications (2)

Publication Number Publication Date
CA2186867A1 CA2186867A1 (fr) 1995-10-19
CA2186867C true CA2186867C (fr) 2000-12-12

Family

ID=22842898

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002186867A Expired - Fee Related CA2186867C (fr) 1994-04-08 1995-03-06 Methodes d'utilisation de chelates contenant du fer pour diminuer les atteintes dues aux radicaux libres chez les mammiferes

Country Status (4)

Country Link
EP (1) EP0754039A4 (fr)
JP (1) JP2001508755A (fr)
CA (1) CA2186867C (fr)
WO (1) WO1995027485A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2746015B1 (fr) * 1996-03-18 1998-04-24 Utilisation de l'octopirox comme agent depigmentant
US5922761A (en) * 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor
TWI234467B (en) 1997-06-04 2005-06-21 Univ Michigan Composition for inhibiting photoaging of skin
EP1013272A1 (fr) * 1998-12-23 2000-06-28 Biomedical Primate Research Centre (BPRC) Manipulation de l'activité d'une voie de production du radical oxyde d'azote pour le traitement de maladies liées à la présence de radicaux libres oxygénés
NL1012825C2 (nl) * 1999-08-13 2001-02-23 Faculteit Geneeskunde Universi Farmaceuticum voor de behandeling van virale infecties in het bijzonder van het humane immunodeficiency virus (HIV).
CN1376049A (zh) * 1999-08-24 2002-10-23 宝洁公司 通过局部施用含肟化合物的组合物增白角质组织的方法
ITMI20022447A1 (it) * 2002-11-19 2004-05-20 Carlo Ghisalberti Uso di piridinoni nel trattamento della purpura capillare ed affezioni cutanee correlate.
WO2005055931A2 (fr) * 2003-12-03 2005-06-23 University Of Medicine And Dentistry Of New Jersey Procede pour empecher la survie des cellules retrovirales et la formation des retrovirus infectieux
CN101679263B (zh) 2007-03-28 2014-01-15 阿普泰克斯科技公司 去铁酮的氟化衍生物
EP2268282B1 (fr) 2008-04-25 2014-10-29 Apotex Technologies Inc. Formulation liquide de défériprone de goût agréable
GEP20146008B (en) 2009-07-03 2014-01-10 Apotex Tech Inc Fluorinated derivatives of 3-hydroxypyridin-4-ones
KR20230004944A (ko) * 2016-08-05 2023-01-06 아브페로 파마슈티칼스, 인크. 금속-매개 상태를 치료하기 위한 투여 요법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3856315T2 (de) * 1987-10-22 1999-10-14 The Procter & Gamble Co. Chelatbildner enthaltende Lichtschutzmittel
ES2199214T3 (es) * 1990-04-26 2004-02-16 THE PROCTER &amp; GAMBLE COMPANY Composiciones quelantes que comprenden compuestos oxima.
WO1992016200A1 (fr) * 1991-03-20 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Utilisation de derives d'acide hydroxamique pour l'inhibition de la replication virale

Also Published As

Publication number Publication date
JP2001508755A (ja) 2001-07-03
EP0754039A4 (fr) 2002-07-17
EP0754039A1 (fr) 1997-01-22
WO1995027485A1 (fr) 1995-10-19
CA2186867A1 (fr) 1995-10-19

Similar Documents

Publication Publication Date Title
EP1002526B1 (fr) Composition pour le blanchiment de la peau contenant un extrait de busserole et un réducteur
EP0787005B1 (fr) Compositions dermatologiques contenant du peroxyde de benzoyle et compose reduisant l&#39;irritation de la peau
TW592714B (en) Composition to enhance permeation of topical skin agents
CA2186867C (fr) Methodes d&#39;utilisation de chelates contenant du fer pour diminuer les atteintes dues aux radicaux libres chez les mammiferes
JP2002212053A (ja) ビタミンｂ３化合物による皮膚外観の調整方法
CN100396287C (zh) 含有电子转移剂磷酸盐衍生物的制剂
RU2199319C1 (ru) Композиции для лечения кожных заболеваний
CN1292699A (zh) 皮肤刺激的处理方法
US20240091171A1 (en) Dermatological compositions and uses thereof
AU616755B2 (en) Topically applied gold organic complex
US5739156A (en) Methods of using 2,4-dienoic acid esters of tocopherols to reduce free radical damage in mammalian cells
CA2086565A1 (fr) Composition pharmaceutique pour traiter la pigmentation
US5922758A (en) Methods and compositions employing 2,4-dienoic acid esters of tocopherols to prevent or reduce skin damage
KR930703252A (ko) 항알레르기성 화장품 또는 약학적, 특히 피부학적 조성물의 제조에 사용되는 쿠쿠르비틴의 용도 및 그의 사용방법
CN1292680A (zh) 皮肤增湿组合物
AU724633B2 (en) Methods of using iron chelating compounds to reduce free radical damage in mammals
WO2003006009A1 (fr) Compositions permettant de reduire la cellulite ou de prevenir son apparition chez les mammiferes
US4520132A (en) Use of undecylenic acid to treat herpes labialis
EP0440249A2 (fr) Ethanolamine pour le traitement de la chéloide
US20050020672A1 (en) Methods of extending mammalian life span via iron chelating compounds that reduce free radical damage in mammals
EP1150671B1 (fr) Composes pyrethroides favorisant la croissance des cheveux
US4391809A (en) Methods for treating psoriasis
CN1145782A (zh) 使用铁螯合化合物来降低哺乳动物中自由基损害的方法
US6284739B1 (en) Antileishmanial composition for topical application
IL272322B2 (en) The compositions for use in the Jericho rose treatment

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed